This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Concert Pharmaceuticals Résultats passés
Passé contrôle des critères 0/6
Informations clés
-45.4%
Taux de croissance des bénéfices
-40.8%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 47.4% |
| Rendement des fonds propres | -94.8% |
| Marge nette | -395.4% |
| Dernière mise à jour des bénéfices | 30 Sep 2022 |
Mises à jour récentes des performances passées
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Ventilation des recettes et des dépenses
Comment Concert Pharmaceuticals gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 22 | 32 | -127 | 22 | 0 |
| 30 Jun 22 | 33 | -125 | 22 | 0 |
| 31 Mar 22 | 33 | -95 | 23 | 0 |
| 31 Dec 21 | 33 | -80 | 23 | 0 |
| 30 Sep 21 | 1 | -66 | 22 | 0 |
| 30 Jun 21 | 2 | -59 | 21 | 0 |
| 31 Mar 21 | 8 | -77 | 20 | 0 |
| 31 Dec 20 | 8 | -75 | 19 | 0 |
| 30 Sep 20 | 8 | -73 | 19 | 0 |
| 30 Jun 20 | 6 | -71 | 19 | 0 |
| 31 Mar 20 | 0 | -77 | 19 | 0 |
| 31 Dec 19 | 1 | -78 | 20 | 0 |
| 30 Sep 19 | 1 | -79 | 21 | 0 |
| 30 Jun 19 | 1 | -79 | 22 | 0 |
| 31 Mar 19 | 1 | -73 | 23 | 0 |
| 31 Dec 18 | 11 | -56 | 23 | 0 |
| 30 Sep 18 | 11 | -41 | 23 | 0 |
| 30 Jun 18 | 11 | 104 | 21 | 0 |
| 31 Mar 18 | 11 | 104 | 21 | 0 |
| 31 Dec 17 | 0 | 95 | 21 | 0 |
| 30 Sep 17 | 0 | 89 | 19 | 0 |
| 30 Jun 17 | 0 | -50 | 18 | 0 |
| 31 Mar 17 | 0 | -50 | 16 | 0 |
| 31 Dec 16 | 0 | -51 | 14 | 0 |
| 30 Sep 16 | 10 | -38 | 14 | 0 |
| 30 Jun 16 | 12 | -35 | 14 | 0 |
| 31 Mar 16 | 15 | 19 | 13 | 0 |
Des revenus de qualité: CNCE is currently unprofitable.
Augmentation de la marge bénéficiaire: CNCE is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CNCE is unprofitable, and losses have increased over the past 5 years at a rate of 45.4% per year.
Accélération de la croissance: Unable to compare CNCE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: CNCE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.2%).
Rendement des fonds propres
ROE élevé: CNCE has a negative Return on Equity (-94.78%), as it is currently unprofitable.